p53 codon 72 polymorphism and breast cancer risk: A meta-analysis
- Authors:
- Jing Hou
- Yuan Jiang
- Wenru Tang
- Shuting Jia
-
Affiliations: Laboratory of Molecular Genetics of Aging and Tumor, Medical Faculty, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China, Laboratory of Molecular Genetics of Aging and Tumor, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China - Published online on: March 20, 2013 https://doi.org/10.3892/etm.2013.1019
- Pages: 1397-1402
This article is mentioned in:
Abstract
Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI | |
Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006. View Article : Google Scholar : PubMed/NCBI | |
Veronesi U, Boyle P, Goldhirsch A, et al: Breast cancer. Lancet. 365:1727–1741. 2005. View Article : Google Scholar : PubMed/NCBI | |
Bartkova J, Lukas J, Strauss M and Bartek J: Cyclin D1 onco-protein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene. 10:775–778. 1995.PubMed/NCBI | |
Porter-Jordan K and Lippman ME: Overview of the biologic markers of breast cancer. Hematol Oncol Clin North Am. 8:73–100. 1994.PubMed/NCBI | |
Callahan R, Cropp CS, Merlo GR, et al: Somatic mutations and human breast cancer. A status report Cancer. 69(Suppl): 1582–1588. 1992.PubMed/NCBI | |
Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI | |
Li Z, Ni M, Li J, Zhang Y, Ouyang Q and Tang C: Decision making of the p53 network: Death by integration. J Theor Biol. Dec 3–2010.(Epub ahead of print). | |
Brosh R and Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 9:701–713. 2009.PubMed/NCBI | |
Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG and Harris CC: Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J Pathol. 187:8–18. 1999. View Article : Google Scholar : PubMed/NCBI | |
Ravi R, Mookerjee B, Bhujwalla ZM, et al: Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:34–44. 2000.PubMed/NCBI | |
Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC and Yang PC: Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol. 20:900–910. 2002. View Article : Google Scholar : PubMed/NCBI | |
Mhawech P, Kinkel K, Vlastos G and Pelte MF: Ovarian carcinomas in endometriosis: an immunohistochemical and comparative genomic hybridization study. Int J Gynecol Pathol. 21:401–406. 2002. View Article : Google Scholar : PubMed/NCBI | |
Zhou Y, Li N, Zhuang W, et al: P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 121:1481–1486. 2007. View Article : Google Scholar : PubMed/NCBI | |
Harris N, Brill E, Shohat O, et al: Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol. 6:4650–4656. 1986.PubMed/NCBI | |
Dumont P, Leu JI, Della Pietra AC III, et al: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 33:357–365. 2003. View Article : Google Scholar : PubMed/NCBI | |
Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI | |
DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI | |
Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y and Zhang Z: P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat. 120:509–517. 2010. View Article : Google Scholar : PubMed/NCBI | |
Damin AP, Frazzon AP, Damin DC, et al: Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev. 30:523–529. 2006. View Article : Google Scholar : PubMed/NCBI | |
Själander A, Birgander R, Hallmans G, et al: p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 17:1313–1316. 1996. | |
Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT and Kotsis A: The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett. 222:57–65. 2005. View Article : Google Scholar : PubMed/NCBI | |
Akkiprik M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H, Demirkalem P, Abacioglu U, Sengoz M, Sav A and Ozer A: Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. Pathol Oncol Res. 15:359–368. 2009. View Article : Google Scholar : PubMed/NCBI | |
Buyru N, Tigli H and Dalay N: P53 codon 72 polymorphism in breast cancer. Oncol Rep. 10:711–714. 2003. | |
Gochhait S, Bukhari SI, Bairwa N, et al: Implication of BRCA2-26G>A 5′ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res. 9:R712007.PubMed/NCBI | |
Henríquez-Hernández LA, Murias-Rosales A, Hernández González A, et al: Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: A case-control study. Oncol Rep. 22:1425–1433. 2009.PubMed/NCBI | |
Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S and Tajima K: Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer Res. 10:307–311. 2003. View Article : Google Scholar : PubMed/NCBI | |
Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, Husain SA and Das BC: Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem. 252:117–124. 2003. View Article : Google Scholar : PubMed/NCBI | |
Li T, Lu ZM, Guo M, Wu QJ, Chen KN, Xing HP, Mei Q and Ke Y: p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer. 95:2571–2576. 2002. View Article : Google Scholar : PubMed/NCBI | |
Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL and Egan KM: Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis. 28:1680–1686. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB and Chang-Claude J: Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics. 12:269–272. 2002.PubMed/NCBI | |
Weston A and Godbold JH: Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect. 105(Suppl 4): 919–926. 1997. View Article : Google Scholar : PubMed/NCBI | |
Zhang W, Jin MJ and Chen K: Association of p53 polymor-phisms and its haplotypes with susceptibility of breast cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban. 36:561–566. 2007.(In Chinese). | |
Baynes C, Healey CS, Pooley KA, Scollen S, et al SEARCH breast cancer study: Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res. 9:R272007. View Article : Google Scholar : PubMed/NCBI | |
Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Saïd S, Daoud J, Frikha M, Jlidi R and Gargouri A: No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann NY Acad Sci. 1010:764–770. 2003. View Article : Google Scholar : PubMed/NCBI | |
Khadang B, Fattahi MJ, Talei A, Dehaghani AS and Ghaderi A: Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet. 173:38–42. 2007. View Article : Google Scholar : PubMed/NCBI | |
Schmidt MK, Reincke S, Broeks A, et al: Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res. 67:9584–9590. 2007. View Article : Google Scholar : PubMed/NCBI | |
Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimäki A, von Smitten K, Aittomäki K, Heikkilä P, Blomqvist C and Nevanlinna H: Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res. 11:5098–5103. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kawajiri K, Nakachi K, Imai K, Watanabe J and Hayashi S: Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 14:1085–1089. 1993. View Article : Google Scholar : PubMed/NCBI | |
Khaliq S, Hameed A, Khaliq T, et al: P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test. 4:23–29. 2000. View Article : Google Scholar : PubMed/NCBI | |
Mahasneh AA and Abdel-Hafiz SS: Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J. 25:1568–1573. 2004.PubMed/NCBI | |
Noma C, Miyoshi Y, Taguchi T, Tamaki Y and Noguchi S: Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett. 210:197–203. 2004. View Article : Google Scholar : PubMed/NCBI | |
Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC and Sabapathy K: Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev. 14:2245–2252. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wang X, Wei Q and Shen H: Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis. 27:766–771. 2006. View Article : Google Scholar : PubMed/NCBI | |
Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R and Nancy NK: TGFβ1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFβ1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo radiotherapy. Breast Cancer Res Treat. 112:81–87. 2008. | |
Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J, Shao Z and Sabapathy K: MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis. 29:754–761. 2008. View Article : Google Scholar : PubMed/NCBI | |
Singh V, Rastogi N, Mathur N, Singh K and Singh MP: Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol. 18:48–57. 2008. View Article : Google Scholar : PubMed/NCBI | |
Kazemi M, Salehi Z and Chakosari RJ: TP53 codon 72 polymorphism and breast cancer in northern Iran. Oncol Res. 18:25–30. 2009. View Article : Google Scholar : PubMed/NCBI | |
Song F, Zheng H, Liu B, Wei S, Dai H, Zhang L, Calin GA, Hao X, Wei Q, Zhang W and Chen K: An miR-502-binding site single-nucleotide polymorphism in the 3′-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res. 15:6292–6300. 2009. | |
Koh WP, Van Den Berg D, Jin A, Wang R, Yuan JM and Yu MC: Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore. Breast Cancer Res Treat. 130:1011–1019. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kara N, Karakus N, Ulusoy AN, Ozaslan C, Gungor B and Bagci H: P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. DNA Cell Biol. 29:387–392. 2010. View Article : Google Scholar : PubMed/NCBI | |
Leu JD, Wang CY, Tsai HY, Lin IF, Chen RC and Lee YJ: Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer. Oncol Rep. 25:1755–1763. 2011.PubMed/NCBI | |
Wang-Gohrke S, Rebbeck TR, Besenfelder W, et al: p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res. 18:2095–2099. 1998.PubMed/NCBI | |
Papadakis EN, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun. 3:389–392. 2000. View Article : Google Scholar : PubMed/NCBI | |
Suspitsin EN, Buslov KG, Grigoriev MY, et al: Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer. 103:431–433. 2003. View Article : Google Scholar : PubMed/NCBI | |
Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grünewald K, Haun M and Kraft HG: Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer. 90:1989–1994. 2004. View Article : Google Scholar : PubMed/NCBI | |
Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S and Friedman E: The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer. 92:1144–1148. 2005. View Article : Google Scholar : PubMed/NCBI | |
Garcia-Closas M, Kristensen V, Langerød A, et al: Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer. 121:2532–2538. 2007. View Article : Google Scholar : PubMed/NCBI | |
Franeková M, Zúbor P, Stanclová A, Dussan CA, Bohusová T, Galo S, Dobrota D, Kajo K, Péc M and Racay P: Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population. Neoplasma. 54:155–161. 2007.PubMed/NCBI | |
Johnson N, Fletcher O, Palles C, et al: Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet. 16:1051–1057. 2007. View Article : Google Scholar : PubMed/NCBI | |
Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D and Tonin PN: Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer. 8:962008. View Article : Google Scholar : PubMed/NCBI | |
Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R and Schmitt F: Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 8:322008. View Article : Google Scholar : PubMed/NCBI | |
De Vecchi G, Verderio P, Pizzamiglio S, et al: The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev. 32:140–143. 2008.PubMed/NCBI | |
Nordgard SH, Alnaes GI, Hihn B, et al: Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. Int J Cancer. 123:577–585. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lång A, Palmebäck Wegman P and Wingren S: The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. Oncol Rep. 22:575–579. 2009.PubMed/NCBI | |
Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH and Watanabe MA: CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med. 23:429–435. 2009.PubMed/NCBI | |
Hrstka R, Beranek M, Klocova K, Nenutil R and Vojtesek B: Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncol Rep. 22:1205–1211. 2009.PubMed/NCBI | |
Bisof V, Salihović MP, Narancić NS, Skarić-Jurić T, Jakić-Razumović J, Janićijević B, Turek S and Rudan P: TP53 gene polymorphisms and breast cancer in Croatian women: a pilot study. Eur J Gynaecol Oncol. 31:539–544. 2010.PubMed/NCBI | |
Ebner F, Schremmer-Danninger E and Rehbock J: The role of TP53 and p21 gene polymorphisms in breast cancer biology in a well specified and characterized German cohort. J Cancer Res Clin Oncol. 136:1369–1375. 2010. View Article : Google Scholar : PubMed/NCBI | |
Alshatwi AA, Hasan TN, Shafi G, Alsaif MA, Al-Hazzani AA and Alsaif AA: A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population. Fundam Clin Pharmacol. 26:438–443. 2012. View Article : Google Scholar : PubMed/NCBI | |
Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, Rafeek M, Akil N and Alkhalaf M: P53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol. 28:709–715. 2011. View Article : Google Scholar : PubMed/NCBI | |
Weston A, Ling-Cawley HM, Caporaso NE, et al: Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis. 15:583–587. 1994. View Article : Google Scholar : PubMed/NCBI | |
Helland A, Langerød A, Johnsen H, Olsen AO, Skovlund E and Børresen-Dale AL: p53 polymorphism and risk of cervical cancer. Nature. 396:530–531. 1998. View Article : Google Scholar : PubMed/NCBI | |
Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ and De Vivo I: The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses’ health studies. Cancer Causes Control. 18:621–625. 2007.PubMed/NCBI | |
Gaudet MM, Gammon MD, Bensen JT, Sagiv SK, Shantakumar S, Teitelbaum SL, Eng SM, Neugut AI and Santella RM: Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York. Breast Cancer Res Treat. 108:93–99. 2008. View Article : Google Scholar : PubMed/NCBI | |
Denisov EV, Cherdyntseva NV, Litvyakov NV, et al: TP53 mutations and Arg72Pro polymorphism in breast cancers. Cancer Genet Cytogenet. 192:93–95. 2009. View Article : Google Scholar : PubMed/NCBI |